A vaccine that reaches a clinic at the wrong temperature is not a vaccine anymore. It is a vial of protein that looks exactly like the real thing but does nothing, and in many countries, nobody finds out until a child gets sick anyway.
By Santhosh Vishwamitra
Executive Summary
Getting a vaccine from a laboratory to a child's arm in a remote village involves one of the most technically demanding logistics operations on earth. The cold chain must be maintained without a single break. The last mile must be reached without reliable roads, electricity, or communications infrastructure. The politics of who gets vaccines first must somehow be resolved before the doses expire. This guide covers how global vaccine distribution works, where it consistently breaks down, what COVID-19 and the COVAX experience revealed about its structural weaknesses, and what the combination of drones, digital monitoring, and decentralised manufacturing is beginning to change.
What is global vaccine logistics?
Global vaccine logistics is the end-to-end process of manufacturing, storing, transporting, and administering vaccines across international supply chains while maintaining strict temperature integrity. It spans four layers: international transport from manufacturer to country, national distribution from ports or airports to regional warehouses, sub-national delivery to district health facilities, and last-mile delivery to the point of care. Each layer has distinct technical requirements, and a failure at any point renders the doses useless.
Why Vaccine Distribution Is Uniquely Difficult
Most goods can tolerate a delay, a temperature fluctuation, or a customs hold without becoming permanently useless. Vaccines cannot. They are biological products engineered to trigger a specific immune response, and that response depends entirely on the biological structures arriving intact at the point of administration. Heat denatures proteins. Freezing damages adjuvants. Light degrades some formulations. A consignment of car parts sitting in a hot warehouse is inconvenient. A consignment of vaccines doing the same thing is invisible waste, and the consequences show up months later in disease outbreak data.
The second complication is demand unpredictability. Routine childhood immunisation programs follow relatively stable schedules. Pandemic response does not. When COVID-19 vaccines became available in late 2020, the world needed to distribute billions of doses across 190-plus countries within months, using infrastructure that had never been tested at that scale. The system was also asked to handle a new technology: mRNA vaccines requiring ultra-cold storage at temperatures colder than most parts of Antarctica.
The third layer is political. Vaccines are not simply goods. They are instruments of national policy, international diplomacy, and commercial competition. Who gets them first, at what price, through which channels, and with what conditions attached are all negotiated questions. The technical logistics problem sits inside a political economy that frequently makes the technical problem harder to solve.
The Cold Chain: What It Is and Where It Breaks
The cold chain is the unbroken sequence of temperature-controlled storage and transport that a vaccine must travel through from the moment it leaves the manufacturing facility to the moment it is administered. Over 90% of approved vaccines and biologics depend on it. A temperature excursion at any point can compromise vaccine potency, sometimes without any visible change to the vial, and may require the affected doses to be quarantined or discarded. Whether a specific excursion destroys a batch depends on the vaccine type, the temperature reached, the duration, and the manufacturer's cumulative stability data.
Imagine a nurse in northern Nigeria opening a vaccine vial that has been correctly stored at every point along a 4,000-kilometre journey, except for three hours in a malfunctioning refrigerator at a district health centre. The vial looks identical to a viable one. The nurse has no way of knowing. She administers the dose. The child receives nothing of value. Neither of them will find out.
This is not a hypothetical. One industry analysis estimates that close to a quarter of vaccines are damaged due to cold chain malfunction in distribution and shipping, though global figures vary widely by vaccine type, country, and methodology, and overall wastage rates reported in some studies run considerably higher. The problem is worst at the last node of the chain, where power supply is unreliable, refrigeration equipment is old, and supervision is limited.
The WHO's 2025 guidelines on vaccine shipping marked a significant shift in how the industry thinks about this. The new standard draws a clear distinction between passive temperature control, insulated packaging that slows heat transfer, and advanced active systems that monitor, regulate, and report temperature in real time. The shift is from maintaining temperature to assuring it. Gavi's ColdTrace monitoring devices, deployed in 43 countries between 2021 and 2025, have been associated with up to 80% reduction in vaccine losses at participating sites, alongside a 63% reduction in cold chain equipment downtime.
One Decision That Changed Everything: When the Pfizer-BioNTech COVID-19 vaccine launched in late 2020 requiring storage at around -70°C, it exposed a gap that nobody had fully planned for. Most national cold chain infrastructure was built for the standard 2–8°C range. COVAX's early supply strategy, centred on the Serum Institute of India, was designed around conventional cold chain-compatible vaccines. Those two facts, the ultra-cold requirement of the first prominent mRNA vaccine and the conventional infrastructure underlying COVAX's supply model, were distinct problems. Together they made the early distribution gap between wealthy and low-income countries considerably harder to close.
Key Terms
| Term |
What It Means |
| Cold Chain |
The unbroken sequence of temperature-controlled storage and transport that vaccines must pass through from manufacturer to patient. A temperature excursion can compromise potency, sometimes without any visible sign, and may require doses to be assessed, quarantined, or discarded. |
| VVM (Vaccine Vial Monitor) |
A small heat-sensitive label attached to a vaccine vial that changes colour if the cumulative heat exposure has exceeded safe limits. Simple, cheap, and widely used as a first-line cold chain indicator. |
| Last Mile |
The final leg of delivery from a district health facility to the actual point of care, often a rural clinic or outreach post. Consistently the hardest and most expensive part of the distribution chain. |
| Ultra-Cold Chain |
Storage and transport at -60°C to -80°C, required for mRNA vaccines. Distinct from the standard 2-8°C cold chain and requires specialised equipment not widely available in low-income countries. |
| COVAX |
COVID-19 Vaccines Global Access Facility. A multilateral initiative led by Gavi, CEPI, and the WHO to ensure equitable global access to COVID-19 vaccines. Delivered close to 2 billion doses to lower-income countries. |
| Vaccine Nationalism |
The practice of governments securing vaccine supplies exclusively for their own populations, often through advance purchase agreements that leave multilateral initiatives under-supplied. |
| vLMIS |
Vaccine Logistics Management Information System. A national digital platform for tracking doses, managing inventory, and planning replenishments across the supply chain. |
| CCEOP |
Cold Chain Equipment Optimization Platform. A Gavi initiative that funds and coordinates the deployment of solar-powered refrigerators and other cold chain equipment in low-income countries. |
| Advance Purchase Agreement |
A contract between a government or institution and a vaccine manufacturer, committing to buy a specified number of doses at a set price before the vaccine is approved. Gives manufacturers financial certainty to produce at scale but concentrates supply access in wealthy buyers. |
The Four Layers of Distribution
Vaccine distribution does not operate as a single supply chain. It operates as four overlapping systems, each with its own actors, failure modes, and bottlenecks.
Layer 1: International Transport. Vaccines move from manufacturing facilities, concentrated in India, China, the United States, and Europe, to destination countries primarily by air freight. Temperature-controlled cargo containers are used for standard vaccines. Ultra-cold chain shipments require dry ice replenishment every 24 to 48 hours, creating a logistics dependency at every transfer point. Customs clearance adds another variable: delays at ports of entry can expose vaccine shipments to ambient temperatures for hours. A single bureaucratic hold can breach the cold chain without anyone registering it as a loss.
Layer 2: National Distribution. Once vaccines clear customs, they move to national warehouses or cold stores, typically maintained by the Ministry of Health or its contracted logistics partners. This layer has improved significantly in many countries since 2020. In Ethiopia, outsourcing last-mile delivery from public to private logistics firms more than doubled vaccine availability at the end of the delivery chain, from 41% to 95%, while simultaneously cutting cost per mile. The lesson from that programme is that the public sector does not always need to operate logistics directly. What it needs to do is set standards and hold contractors accountable.
Layer 3: Sub-National Delivery. From national warehouses, vaccines move to regional and district health facilities. This is where the cold chain pressure intensifies. Power supply becomes less reliable. Road quality varies. The equipment is older. The supervision is thinner. This layer is where most cold chain failures actually occur, not at the international shipping stage where monitoring is tightest.
Layer 4: Last Mile. The final delivery from district facility to point of care is the hardest problem in vaccine logistics. It often requires reaching clinics accessible only by unpaved roads that wash out in rainy season, or village outreach posts with no refrigeration at all. This is where drones, solar refrigerators, and vaccine vial monitors matter most.
Where the Chain Can Break
| Stage |
Typical Failure |
Consequence |
| Manufacturing |
Packaging error; temperature breach during fill-finish |
Batch compromised before it leaves the facility |
| International Transport |
Customs delay; dry ice exhausted on long-haul ultra-cold shipment |
Temperature excursion; doses may require quarantine assessment |
| National Warehouse |
Power outage; refrigeration failure; overcooling causing freeze |
Potency loss across entire stock batch; freeze damage often undetected |
| District Facility |
Old equipment; staff training gaps; power intermittency |
Silent potency loss; VVMs detect heat but not freeze events |
| Last Mile / Clinic |
No transport; no outreach funding; stock-out or expired stock |
Doses expire unused; communities miss scheduled immunisation window |
| Patient |
Vaccine hesitancy; access barriers; missed appointments |
Dose is available but never administered; immunisation gap persists |
The table reveals something important. A dose sitting safely in a warehouse is not health protection. A dose delivered to a clinic refrigerator is not health protection. Only an appropriately stored dose actually administered to the intended person becomes immunisation. Every step between production and arm is a point where that outcome can fail.
Temperature Requirements by Vaccine Type
| Vaccine Type |
Storage Temperature |
Examples |
Key Logistics Challenge |
| Live Attenuated |
2°C to 8°C, some freeze-sensitive |
MMR, Yellow Fever, Oral Polio |
Light and heat sensitive; some cannot be refrozen once thawed |
| Inactivated / Subunit |
2°C to 8°C |
Hepatitis B, DTP, IPV |
Freeze damage is common and often undetected; VVMs do not detect freeze events |
| mRNA |
-60°C to -80°C (original); newer formulations 2-8°C |
Pfizer-BioNTech COVID-19, Moderna COVID-19 |
Ultra-cold infrastructure is expensive and rare in low-income settings |
| Viral Vector |
2°C to 8°C |
AstraZeneca COVID-19, Ebola vaccines |
Relatively stable; more suitable for low-resource settings than mRNA |
| Toxoid |
2°C to 8°C, freeze-sensitive |
Tetanus, Diphtheria |
Freezing destroys adjuvants; routine doses suffer silent freeze damage frequently |
The table above understates one critical problem. Freeze damage to vaccines stored in the 2-8°C range is far more common than heat damage in many settings, because health workers often err toward overcooling rather than risk heat exposure. Frozen vaccines look intact. They fail silently at the point of administration.
COVAX: What It Got Right and What It Got Wrong
COVAX was built on a reasonable premise. By pooling demand from both wealthy and low-income countries, the initiative would aggregate enough purchasing power to secure advance supply agreements with manufacturers and prevent wealthy nations from hoarding vaccines through bilateral deals. The mechanism was elegant. The execution collapsed almost immediately upon contact with political reality.
In January 2021, the WHO's director-general described the emerging disparity in vaccine access as placing the world on the "brink of a catastrophic moral failure." A year later, the failure had arrived. Data from April 2021, cited in a 2025 peer-reviewed analysis in Global Public Health (Li et al.), showed that close to 87% of all COVID-19 vaccines administered globally had gone to high-income countries or upper-middle-income regions. Low-income countries had received roughly 0.2% of all doses administered at that point.
The first structural problem was the reliance on a single primary supplier. COVAX had concentrated its supply agreements heavily on the Serum Institute of India. In March 2021, just as COVAX was beginning to distribute doses, India halted all vaccine exports to manage its own catastrophic second wave. COVAX lost its primary supply source overnight and had no adequate backup.
The second problem was vaccine nationalism. High-income countries had entered bilateral advance purchase agreements with manufacturers before COVAX was fully operational. Those agreements gave manufacturers certainty of demand, but they also meant that COVAX was competing for supply with governments that had deeper pockets and more direct relationships with producers. When supply was constrained, COVAX came second.
What COVAX did eventually deliver was substantial. Close to 2 billion doses reached lower-income countries through the initiative, with around three quarters of all doses supplied to low-income countries in certain periods coming through COVAX channels. Modelling suggests COVAX averted a significant proportion of deaths in the countries it reached. The initiative also provided cold chain equipment, technical assistance, and training alongside doses, building infrastructure that will benefit future vaccine programmes. The critique is not that COVAX failed completely. It is that it delivered far less than it promised, far later than it promised, to far fewer countries than it planned, and that the gap was largely created by the behaviour of wealthy nations that were simultaneously championing its mandate.
For a closer look at how disruptions to global supply chains unfold and recover, the Field Guide on Global Supply Chain Recovery covers the broader structural failure modes that were also visible in the vaccine rollout.
The Last-Mile Problem
Most analyses of vaccine distribution identify the last mile as a critical failure point. The description is broadly consistent across contexts: poor transport networks, unreliable power supply for refrigeration, limited real-time inventory visibility, and insufficient health workers to run outreach programmes. The analysis has been consistent for decades. The solutions have arrived slowly.
Rwanda is one of the few countries that has genuinely changed the equation. Over 80% of Rwanda's population lives in rural areas. Certain roads become impassable during rainy season. The conventional answer to that geography was to build more roads and more cold stores, at enormous cost and over many years. Rwanda took a different approach. In 2016, working with Zipline and with support from Gavi, it launched the world's first national drone delivery service for medical supplies.
The initial focus was blood products. Zipline drones, flying from centrally located facilities, could deliver blood to rural hospitals within 15 to 45 minutes, compared to hours by road. The reduction in blood product expiration alone justified the programme. Vaccines followed. By 2024, Zipline's drones had delivered over 22 million vaccine doses in Rwanda and Ghana combined, dramatically improving delivery frequency and reliability for communities whose road access was slow, seasonal, or unpredictable.
In 2021, Zipline and Pfizer conducted the world's first long-range drone delivery of mRNA COVID-19 vaccines in Ghana, developing specialised thermal packaging to maintain the required temperature conditions during flight. That was a proof of concept that mattered beyond Ghana: it showed that the ultra-cold chain could, under certain conditions, be extended to communities that would otherwise have required fixed ultra-cold storage infrastructure that does not exist in most low-income country health systems.
Drones, Data, and the New Logistics Toolkit
Drone delivery is the most visible technology changing vaccine logistics, but it is not the most impactful. That distinction belongs to real-time cold chain monitoring, which has been more broadly deployed and has delivered more consistent results across more contexts.
The core of the new approach is the shift from assuming the cold chain is intact to continuously verifying that it is. Traditional cold chain management relied on paper logs updated manually at each transfer point, and on VVMs attached to vials. Both are useful. Neither catches every failure. Real-time monitoring devices, connected to national digital platforms via cellular or satellite network, send temperature alerts when excursions occur, enabling intervention before an entire batch is compromised. In the 43 countries where Gavi has deployed this technology at scale, cold chain losses have dropped by up to 80%.
Solar-powered refrigeration has addressed the power supply problem at rural health facilities, replacing kerosene-powered cold stores that required fuel chains as complex as the vaccine chains themselves. Digital vaccine logistics management information systems, deployed across Sub-Saharan Africa, Southeast Asia, and parts of Latin America, allow national programmes to track doses in near real-time, manage inventory, and plan replenishment before stock-outs occur rather than after.
The combination of these tools is beginning to close the visibility gap that has historically made vaccine waste invisible and therefore unmeasured. You cannot manage what you cannot see. For most of the history of vaccine logistics, what happened at the last mile was effectively invisible to national health programmes. That is changing, slowly and unevenly, but measurably.
The Future Scenario on how CBDCs could reshape global trade by 2032 explores related questions about how digital infrastructure is rewriting the rules of cross-border exchange, including in health supply chains where payment friction adds cost at every tier.
What Most People Miss About This Topic
The public debate about vaccine distribution focuses almost entirely on equity: which countries got vaccines first, how much wealthy nations hoarded, whether COVAX was funded adequately. These are important questions. But they obscure a set of structural problems that would persist even if supply were perfectly equitable.
The first is the manufacturing geography problem. Global vaccine production is concentrated in a small number of countries, primarily India, China, and the United States, with secondary capacity in Belgium, the Netherlands, South Korea, and a few others. This concentration creates a systemic fragility that equity of distribution cannot solve. When the Serum Institute halted exports in March 2021, no amount of COVAX funding could replace the supply that disappeared overnight. The lesson is not only that wealthy countries should share better. It is that the world needs manufacturing capacity distributed across more regions, including Africa, which today produces less than 1% of the vaccines it administers. Domestic vaccine manufacturing growth in India, China, and Brazil is increasing intra-national cold chain capacity, but African manufacturing remains critically underdeveloped.
The second overlooked problem is expiry waste. When wealthy countries did begin donating doses to COVAX and directly to low-income countries in late 2021, many of those doses arrived with very short remaining shelf life. Countries receiving them lacked the distribution infrastructure to reach populations quickly enough to use them before expiry. The waste from expired donated doses was significant and largely unreported. Donation without adequate lead time, cold chain support, and logistical coordination is not generosity. It is cost transfer.
The third gap is the data problem at the clinic level. National health programmes now have reasonable visibility into vaccine stocks at national and regional warehouses. Visibility at the facility level, particularly at small rural clinics and outreach posts, remains thin. Stock-outs and waste both occur at this level without reliable reporting. Gavi's newest strategy explicitly targets this gap with what it describes as a "merger at the last mile," integrating supply chains, data platforms, and delivery routes for immunisation alongside other primary health care services. The idea is that a shared delivery infrastructure for multiple health products is more cost-effective and more sustainable than separate chains for each one. That integration has not yet happened at scale.
Common Misconceptions
Myth: Cold chain failure is mainly a problem of heat exposure.
Reality: Freeze damage is equally common and more insidious. Many vaccines are destroyed by freezing, not heat. Standard VVMs detect heat exposure but not freeze events. Health workers who overcool vaccines to avoid heat damage inadvertently destroy them through freezing. Freeze indicators exist but are not yet universally deployed alongside VVMs.
Myth: COVAX failed because it was underfunded.
Reality: Funding was a constraint, but the primary causes of COVAX's underperformance were structural. Reliance on a single primary supplier without adequate backup, competition from bilateral advance purchase agreements by wealthy nations, and vaccine nationalism by high-income countries that pledged support while simultaneously locking up supply were all more decisive than funding gaps alone. The ACT Accelerator funding gap was close to $16 billion in 2021-22, but even with full funding, the supplier concentration problem would have remained.
Myth: Drones are now solving the last-mile vaccine delivery problem globally.
Reality: Drones are solving it in specific geographies where the model has been validated and funded, primarily Rwanda, Ghana, Nigeria, Kenya, and Ivory Coast. Global deployment faces regulatory barriers, infrastructure requirements for drone launch and charging facilities, payload limitations, and cost structures that currently require ongoing donor support to remain viable. They are a promising solution for certain contexts, not a universal one.
Myth: A donated dose is a delivered dose.
Reality: Donation and delivery are separated by customs clearance, cold chain transport, sub-national distribution, last-mile logistics, trained health workers to administer the dose, and community outreach to bring people to vaccination points. Wealthy countries announcing dose donations without accompanying logistical support and adequate shelf life frequently transferred the problem rather than solving it.
Editorial View · Santhosh Vishwamitra
The story of COVID-19 vaccine distribution is often told as a moral failure: wealthy nations hoarded while poor nations waited. That framing is accurate but incomplete. It treats the problem as one of will, when it is also one of architecture. Even if high-income countries had shared their doses generously from day one, a large portion of those doses would have expired in receiving countries that lacked the cold chain infrastructure, the trained health workers, and the community trust to convert doses into administered vaccines quickly enough.
The more uncomfortable truth is that the world has been aware of the last-mile problem in vaccine distribution for decades. The data on cold chain failures, the data on stock-outs at rural facilities, the data on expired doses at district health centres, all of it existed before 2020. What the pandemic did was make the consequences visible at a scale that could not be ignored. Billions were spent on vaccines. Billions of dollars' worth of those vaccines were wasted or went undelivered. And then the political attention moved on.
What I think matters over the next decade is not the next emergency response. It is whether the infrastructure investments made during COVID-19, the solar refrigerators, the digital tracking systems, the drone networks, the local manufacturing capacity being built in Africa and South Asia, hold and expand when the crisis pressure is off. History suggests they will not without sustained political commitment and reliable funding. The Immunization Agenda 2030, which the World Health Assembly adopted in 2020, sets ambitious targets for exactly this kind of infrastructure. Whether it receives the funding it needs will determine whether the next pandemic response looks meaningfully different from the last one.
Final Thoughts
Vaccine logistics is infrastructure, not administration. That distinction matters. When roads fail, countries build new roads. When power grids are unreliable, countries invest in generation capacity. When vaccine cold chains fail repeatedly, the response has historically been a short-term fix followed by a return to underfunding. The pandemic briefly changed that pattern, but the question is whether the change holds.
The technology is genuinely improving. Real-time monitoring, drone delivery, solar refrigeration, and digital logistics platforms are making the visible parts of the problem tractable. The harder problem is the invisible parts: the doses frozen at district health centres, the stock-outs at rural clinics that generate no report, the doses donated with three weeks of shelf life remaining that expire in customs warehouses. These failures do not produce dramatic images. They produce statistical noise in immunisation coverage data that takes years to interpret.
The world's capacity to distribute vaccines equitably will be tested again. Whether the next test produces a different result depends on decisions being made right now about manufacturing geography, cold chain investment, and the governance of multilateral initiatives. Those decisions are political. The logistics is just where the politics become visible.
Frequently Asked Questions
What is the cold chain and why does it matter for vaccines?
The cold chain is the unbroken sequence of temperature-controlled storage and transport that vaccines must pass through from manufacturing to administration. Vaccines are biological products that degrade when exposed to temperatures outside their required range. A break anywhere in the chain, even briefly, can render an entire batch ineffective without any visible sign of damage. Over 90% of approved vaccines require cold chain management, and an estimated 25% of vaccines globally are lost to cold chain failures each year.
What did COVAX achieve and where did it fall short?
COVAX delivered close to 2 billion doses to lower-income countries, provided free doses to the poorest nations that had no other access, and supported cold chain equipment, training, and technical assistance. Where it fell short was in its timeline and volume targets. Reliance on a single primary supplier, competition from bilateral advance purchase agreements by wealthy nations, and vaccine nationalism by high-income countries caused major delays in the early phase of the rollout. By April 2021, low-income countries had received only 0.2% of globally administered COVID-19 vaccine doses.
Why are mRNA vaccines harder to distribute than traditional vaccines?
The original Pfizer-BioNTech and Moderna COVID-19 vaccines required storage at around -70°C, far colder than the standard 2-8°C range used by most vaccines. Most national cold chain infrastructure was built for the standard range. Ultra-cold storage units are expensive, require specialised maintenance, and were not available at scale in low-income countries when the vaccines were first approved. Newer mRNA formulations have improved thermal stability, but the original rollout exposed a gap between the technology and the distribution infrastructure.
How are drones changing vaccine delivery?
Drones bypass the road network problem entirely, reaching remote clinics in 15 to 45 minutes regardless of whether the roads are passable. Zipline, operating in Rwanda, Ghana, Nigeria, Kenya, and Ivory Coast, has delivered over 22 million vaccine doses by drone, covering communities that conventional distribution could not reliably reach. Zipline and Pfizer conducted the world's first long-range drone delivery of mRNA COVID-19 vaccines in Ghana in 2021. Drones are currently validated in specific geographies and still require donor support to remain cost-effective, but the model is expanding.
What is vaccine nationalism?
Vaccine nationalism is the practice of governments securing vaccine supplies exclusively for their own populations, typically through bilateral advance purchase agreements with manufacturers, before multilateral initiatives like COVAX can access supply. During COVID-19, high-income countries used advance purchase agreements to lock up manufacturing capacity early, leaving COVAX without adequate supply at the critical early phase of the rollout. Vaccine nationalism is widely recognised as having significantly worsened global equity in vaccine access during the pandemic.
Where does most vaccine production take place?
Global vaccine manufacturing is concentrated in India, China, the United States, Belgium, the Netherlands, and South Korea, with secondary capacity in a few other countries. Africa produces less than 1% of the vaccines it uses, despite administering close to 17% of the world's childhood vaccine doses. The African Union has set a target of producing 60% of Africa's vaccines on the continent by 2040, a goal that requires significant investment in manufacturing infrastructure, regulatory capacity, and technology transfer from current producing countries.
Quick Revision: Key Takeaways
- Over 90% of approved vaccines require continuous cold chain management. A temperature excursion can compromise potency, sometimes without any visible sign, and whether an entire batch is lost depends on the vaccine type, temperature reached, duration, and manufacturer stability data.
- An estimated 25% of vaccines are damaged globally each year due to cold chain failures, with freeze damage being as common as heat damage and far less often detected.
- Vaccine distribution operates across four layers: international transport, national distribution, sub-national delivery, and last-mile delivery. Each has distinct failure modes.
- COVAX delivered close to 2 billion doses to lower-income countries but fell far short of its targets, primarily due to supplier concentration risk and vaccine nationalism by high-income countries.
- Real-time cold chain monitoring in 43 countries has reduced vaccine losses by up to 80%, demonstrating that the visibility gap is solvable with available technology.
- Zipline's drone delivery network has delivered over 22 million vaccine doses in Rwanda and Ghana, reaching communities inaccessible by road.
- Africa produces less than 1% of the vaccines it administers. Manufacturing concentration is a systemic vulnerability that equity of distribution cannot solve alone.
- Expired dose donations, arriving with insufficient shelf life for receiving countries to distribute in time, transferred the waste problem from donor to recipient without solving it.
- The WHO's 2025 cold chain guidelines shifted industry standards from maintaining temperature to assuring it, requiring active real-time monitoring rather than passive thermal packaging.
- Sustained infrastructure investment, not emergency response, is what determines whether the next pandemic distribution is meaningfully different from the last one.
Santhosh Vishwamitra
Web Developer and Founder of Vishwamitra Chronicles, launched in February 2026.
Comments
Post a Comment